Introduction

The metabolic syndrome (MetS) is a collection of related risk factors that increases the risk of type 2 diabetes, cardiovascular disease, stroke and other diseases. Individuals with MetS have a 5-fold greater risk of developing type 2 diabetes and are 3 times more likely to have a heart attack or stroke compared with those without the syndrome [1]. According to the International Diabetes Federation, the worldwide prevalence of MetS is 25% and increasing rapidly [2].

The International Diabetes Federation published a worldwide definition of MetS based on central obesity defined as waist circumference with ethnicity-specific values, plus any two of the following four factors: plasma

more important that weight gain during pregnancy for reducing the risk of obesity in the offspring. The effects of different polyunsaturated fatty acids on MetS and weight loss require clarification.

© 2014 S. Karger AG, Basel

Key Words
Dietary fat quality · Metabolic syndrome · Obesity · Weight loss

Abstract
A symposium on the health significance of dietary fat in the prevention and treatment of the metabolic syndrome (MetS) was held at the 20th International Congress of Nutrition in Granada, Spain, on September 19, 2013. Four nutrition experts addressed the topics of dietary fat and obesity, effects of dietary fat quality in obesity and insulin resistance, influence of early nutrition on the later risk of MetS and the relative merits of high- or low-fat diets in counteracting MetS. Participants agreed that preventing weight gain and achieving weight loss in overweight and obese patients were key strategies for reducing MetS. Both low-fat and low-carbohydrate diets are associated with weight loss, but adherence to the diet is the most important factor in achieving success. Avoidance of high saturated fats contributes to lower health risks among obese, MetS and diabetic patients. Further, healthy maternal weight at conception and in pregnancy is

© 2014 S. Karger AG, Basel

0250–6807/14/0642–0167$39.50/0
www.karger.com/anm

This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
triglycerides ≥1.7 mmol/l (150 mg/dl); high-density-lipoprotein cholesterol <1.03 mmol/l (<40 mg/dl) in males or <1.29 mmol/l (<50 mg/dl) in females; blood pressure: systolic pressure ≥130 or diastolic pressure ≥85 mm Hg, and fasting plasma glucose ≥5.6 mmol/l (≥100 mg/dl) [2]. It is generally agreed that insulin resistance is the principal metabolic abnormality in MetS [3, 4] and is reflected in the assessment of abdominal obesity, which is easier to measure clinically.

The prevalence of MetS parallels the rising rates of obesity [5], although approximately 30% of obese individuals maintain healthy cardiometabolic profiles [6]. Similarly, not all those with insulin resistance are obese [7]. Those with abdominal obesity have the highest risk of MetS and type 2 diabetes [8]. Intervention studies have shown that weight loss and lifestyle intervention reduce the risk of progression to type 2 diabetes [9, 10]. Improvements in diet quality beyond macronutrient distribution are significantly associated with reductions in weight, fat mass and visceral adipose tissue in MetS individuals following an energy-restricted, lifestyle intervention program for 1 year [11]. Two questions arise about the role of dietary fat in MetS: to what extent do dietary fat and fat quality contribute to weight gain or loss, and what are their effects on the development of MetS independent of weight? To address these topics, the International Expert Movement to Improve Dietary Fat Quality [12], an initiative of the International Union of Nutritional Sciences, funded by an unrestricted educational grant from Unilever NV, hosted a symposium at the 20th International Congress of Nutrition in Granada, Spain, on September 19, 2013. This paper summarizes that symposium.

**Dietary Fat and Obesity**

Susan Jebb, professor of diet and population health, Oxford University, UK, traced the research on fat intake and obesity from ecological studies through controlled intervention trials and comparisons among popular weight loss programs. Her presentation addressed the question whether reducing total fat intake is crucial in weight loss or whether total energy intake matters more. Although cross-cultural studies demonstrated a linear relationship between dietary percent energy (%E) from fat and percent of overweight individuals in the population [13], studies among more homogeneous populations found no association [14]. Yet the efficient absorption of fat and its relative resistance to oxidation, compared with carbohydrates, suggest that high-fat diets could be particularly liable to lead to weight gain. Experimental studies have also suggested that high-fat foods are only weakly satiating relative to other macronutrients and may contribute to passive overconsumption and excess energy intake [15, 16].

Detailed studies on macronutrient balance in humans during overfeeding, conducted within whole-body calorimeters, showed that while carbohydrate was readily oxidized, fat oxidation decreased as overfeeding continued, leading to fat accumulation [17]. During periods of underfeeding, fat oxidation remained high and unrelated to fat intake. Studies of men confined to a whole-body calorimeter showed that as the energy density of the diet increased (covert manipulations), ad libitum energy consumption also increased [18]. However, when the energy density of diets was held constant and the %E from fat increased from 20 to 60%, total energy intake remained constant (fig. 1) [19]. Other experimental studies have consistently demonstrated that energy intake increases with increasing energy density [16].

However, longer-term trials involving fat manipulations are less clear. The largest long-term randomized controlled study of low-fat diets and weight loss, the Women’s Health Initiative, reported in a secondary analysis that the mean weight loss from baseline in women with a body mass index (BMI) >30 over 7.5 years was greatest among those who decreased their %E from fat the most [20]. Mean weight loss was significantly related to %E from fat, with those who consumed the highest %E from fat actually gaining weight.
Yet in a well-controlled intervention study comparing the effectiveness of three energy-restricted diets, low fat (30%E from fat), Mediterranean (33%E from fat) and high fat/low carbohydrate (39%E from fat), on weight loss in moderately obese participants, Shai et al. [21] reported that after 2 years those following the low-carbohydrate or Mediterranean diets lost significantly more weight (4.7 and 4.4 kg, respectively) than those on the low-fat diet (2.9 kg). After an additional 4 years without intervention, participants in the high-fat group regained 4.1 kg, those in the low-fat group 2.7 kg and those following the medium-fat Mediterranean diet 1.4 kg (p = 0.004 for all comparisons) [22]. Over the 6-year period, those on the Mediterranean diet had a significantly greater weight loss (3.1 kg) compared with the low-fat (0.6 kg) and high-fat (1.7 kg) diet groups. Differences in weight loss between the low-fat and high-fat/low-carbohydrate groups were not significant.

In a systematic review and meta-analysis of 33 randomized controlled trials and 10 cohort studies on the relation between total fat intake and body weight, Hooper et al. [23] concluded that high-quality evidence supports the association between lower fat intake and small but significant sustained reductions in body weight. Greater reductions in total fat and higher baseline fat intakes were associated with greater weight loss. The association was less clear in the 10 cohort studies where only 31% reported a significant positive association between fat content and weight gain, while in studies longer than 1 year, only half showed a significant positive association. However, all studies except 1 showed a high risk of bias.

Data from pragmatic trials of dietary interventions for weight loss show the high interindividual variability in response, suggesting the outcome may depend on factors other than the fat content of the diet. For example, a community-based open study of participants whose BMI ranged from 27 to 40 compared 4 popular weight loss programs of variable fat content with a control group who maintained their regular diet. After 6 months, all groups lost weight compared with the control group, but the mean weight loss did not differ among the programs [24]. Likewise, a similar study comparing 4 weight loss diets, including the low-fat Ornish diet and high-fat Atkins diet, reported that after 1 year, participants in each diet group lost modest amounts of weight, but the amount did not differ among diets and interindividual variability was high [25]. Increased self-reported dietary adherence was associated with greater weight loss irrespective of diet.

Jebb concluded by noting that any dietary strategy to prevent or treat obesity must address total energy intake rather than fat content per se and include behavioral strategies to maximize adherence. However, since the ultimate goal of weight loss among overweight and obese individuals is to reduce health risks, especially the burden of cardiovascular disease, it is important to consider the fatty acid composition of the diet to maximize broader health benefits.

### Fat Quality in Obesity and Insulin Resistance

Ulf Risérus, associate professor of clinical nutrition and metabolism, Uppsala University, Sweden, discussed the involvement of dietary fatty acids in the development of obesity, insulin resistance and type 2 diabetes. In insulin resistance and obesity, plasma levels of free fatty acids increase because of the impaired ability of the liver, adipose tissue and skeletal muscle to take up and convert the fatty acids to glucose or store them as triglycerides. However, as adipose tissue increases, the release of free fatty acids per kilogram adipose tissue may be downregulated, so that free fatty acid concentrations in plasma may be in the normal range [26]. Insulin resistance is also associated with long-term lipid overload, as observed in the accumulation of lipids outside subcutaneous adipose tissue (ectopic fat), such as skeletal muscle, visceral and liver fat. This may result from impaired lipid deposition in adipose tissue and impaired oxidative capacity [26]. Thus, dietary effects on body weight and total body fat are expected to have less favorable metabolic effects unless abdominal and ectopic fat are decreased as well.

Dietary fat quality affects the risk of diabetes, and insulin resistance and sensitivity in healthy, obese and diabetic individuals. High serum levels of saturated fatty acids (SFA) were reported to predict the development of MetS [27], while the risk of diabetes was inversely associated with vegetable fat, polyunsaturated fatty acid (PUFA) intakes and higher serum levels of ω–6 (n–6) PUFAs [28, 29]. However, in a large prospective cohort of women followed for 14 years, the risk of type 2 diabetes was not associated with saturated or monounsaturated fat consumption, but was significantly reduced with higher intakes of PUFA [30].

The effects of different types of dietary fatty acids on obesity and fat accumulation have not been extensively investigated. Controlled feeding studies in animals indicate that in general SFA are more fattening than similar intakes of PUFA. For example, in mice fed corn oil (high in linoleic acid, the major dietary n–6 PUFA), only 31% of the intake was deposited, whereas 56% was deposited...
in mice fed a beef tallow diet (high palmitic acid, the major dietary SFA). Some evidence suggests that diets high in SFA increase the risk of obesity [31] and weight gain [32] and reduce insulin sensitivity [33]. In a small crossover study of obese men, substitution of SFA with monounsaturated fat for 4 weeks was associated with significantly lower body weight and fat mass without a change in energy or fat intake [34]. A lifestyle study for the reduction in high blood pressure reported that a higher intake of SFA at 6 months was associated with greater weight at 18 months, whereas a lower SFA intake predicted lower body weight [32]. It has been shown in several controlled feeding studies that palmitic acid results in lower fat oxidation than diets rich in monounsaturated fatty acids [35].

A large trial among obese participants with MetS in 8 countries reported that reducing SFA intake by increasing monounsaturated fat or ω–3 (n–3) PUFA or carbohydrate had no effect on insulin sensitivity when weight was stable [36]. However, a previous multicenter trial indicated a beneficial insulin-sensitizing effect of such a dietary fat modification, especially when the total fat content did not exceed 37%E [37]. Thus, the interventional data on monounsaturated fatty acids and insulin sensitivity are inconclusive, but no large trials replacing SFA with n–6 PUFA have been conducted.

Data on the effect of increasing PUFA at the expense of SFA remain limited and inconsistent. Research in animals and humans suggest that PUFA are associated with improved weight loss in some studies, but not others [38]. In a study of individuals with type 2 diabetes, obesity without diabetes or nonobese participants, substitution of SFA with PUFA (mainly n–6 PUFA) for 5 weeks on each diet in a crossover design resulted in improved insulin sensitivity and reduced abdominal subcutaneous fat area compared with the SFA diet [39]. A comparison of conjugated linoleic acid with safflower oil (78% linoleic acid) on weight loss in obese women with type 2 diabetes reported a lower BMI and total adipose mass after 16 weeks with conjugated linoleic acid, while higher safflower oil intake was associated with lower trunk adipose mass and fasting glucose, with no change in BMI [40]. These findings support the results reported by Summers et al. [39] and suggest a potential reduction of abdominal fat and improvement of glucose metabolism by n–6 PUFA in obese diabetic individuals.

Swedish investigators compared the effects of isocaloric diets rich in either PUFA (mainly n–6 PUFA) or SFA on liver fat and metabolic parameters in participants with abdominal obesity, 15% of whom had type 2 diabetes [41]. Participants consuming foods high in n–6 PUFA experienced a significant reduction in liver fat measured by magnetic resonance imaging, which was inversely related to the increased serum linoleic acid levels. Compared with the PUFA diet, those on the SFA-rich diet exhibited increased liver fat. In addition, PUFA significantly reduced the visceral fat/subcutaneous fat ratio compared with the SFA diet. Despite weight-stable conditions, the PUFA-rich diet was associated with moderate improvements in blood lipids and fasting insulin, whereas the SFA diet was not. This is the first study to demonstrate a favorable effect of PUFA-rich foods on ectopic fat content in humans, independent of weight change.

In a recent study of overfeeding normal-weight individuals with foods high in SFA or n–6 PUFA for 7 weeks, those fed the SFA-rich foods had markedly increased liver fat and a 2-fold larger increase in visceral fat compared with the PUFA group (fig. 2) [42]. Those consuming the PUFA-rich foods had a nearly 3-fold larger increase in lean tissue compared with the SFA group. The investigators concluded that in healthy humans overeating SFA-rich foods promotes hepatic and visceral fat storage, whereas excess energy from n–6 PUFA was associated with increased lean tissue. These findings are consistent with the observations reported in individuals with abdominal obesity [41].

n–3 PUFA may have different effects from linoleic acid. Most research has focused on the long-chain (LC) n–3 PUFA, primarily eicosapentaenoic acid and docosahexaenoic acid found mainly in fish and shellfish. Rodent studies have shown that fish oil or n–3 LC-PUFA can reduce diet-induced obesity [43], have a hypolipidemic effect on the liver [44], increase fatty acid oxidation in adipose tissue [45], inhibit fat cell proliferation [46], limit fat cell hypertrophy and hyperplasia [47], and stimulate mitochondrial biogenesis and β-oxidation in white adipose tissue [48]. Thus, an extensive literature of animal studies supports the anti-obesity effects of n–3 LC-PUFA.

Studies on the effects of n–3 PUFA in humans are scarce [49]. Data from epidemiological studies are inconsistent, but several large studies reported an inverse association between fish consumption or n–3 LC-PUFA intake and BMI or abdominal obesity [50, 51]. In severely obese women following a very-low-calorie diet, the addition of 2.8 g/day of n–3 LC-PUFA was associated with a significantly greater loss in BMI and hip circumference compared with unsupplemented participants [52]. However, the addition of supplemental n–3 LC-PUFA to a 24-week diet and exercise program provided no additional benefit for weight loss in overweight and obese individu-
als [53]. In contrast, the addition of a daily fish meal to a weight loss diet was more effective than the weight loss diet alone in achieving weight loss over 16 weeks [54]. Fish consumption was not associated with 5- to 10-year weight gain in a large prospective cohort study [55]. In a controlled 16-week study in overweight and moderately obese healthy adults, increasing the dietary content of n–3 PUFA to 3.6%E mainly from fish oil had no effect on body weight or fat mass [56]. A recent review reached a similar conclusion [57]. Thus, fish or n–3 PUFA intakes may have little effect on body weight or weight gain.

Suggestive data, although limited, indicate that dietary fat quality may affect the development of adipose tissue accumulation and distribution. The effect of dietary fat quality in modulating ectopic fat is of clinical interest, as liver fat is closely linked to type 2 diabetes. As knowledge grows, it may be possible to compose optimal diets that minimize abdominal and ectopic fat accumulation, thereby helping to prevent obesity and its related metabolic disorders.

**Early Lipid Nutrition and Later Risk of MetS**

Recognizing the rising tide of obesity and type 2 diabetes, Prof. Berthold Koletzko, University of Munich Medical Center, Munich, Germany, emphasized the importance of early intervention to prevent obesity. Halting the epidemic of overweight and obesity is urgent because of the many adverse health conditions linked to obesity, the extension of the disorder into early childhood, and the growing prevalence of obesity in lower-income countries [58]. In the US, more than 35% of adults and 17% of children and adolescents were obese in 2009–2010 [59].

Efforts to better understand the etiology of obesity beyond overeating and physical inactivity call attention to events in fetal and early life. Studies on early programming during fetal and postnatal life suggest interventions with the potential to deter obesity [60]. So compelling is the problem and the importance of early nutrition that a worldwide project to investigate the long-term effects of...
early nutrition on later health has been initiated, which was funded by the European Union [61].

Three hypotheses for early developmental programming for obesity have been proposed: (1) ‘fetal overnutrition’ suggests that excess exposure to fuels, as occurs in gestational diabetes, causes changes that lead to obesity [62]; (2) accelerated postnatal weight gain proposes an association between rapid weight gain in infancy and an increased risk of later obesity [63], and (3) mismatch between fetal undernutrition and postnatal overnutrition suggests that experiencing suboptimal fetal nutrition and an obesogenic childhood environment predisposes to obesity. A well-known example of the latter is the survivors of the Dutch famine in the winter of 1944–1945, many of whom were born small for gestational age and later experienced increased incidence of obesity, diabetes and other chronic diseases [64].

Excessive perinatal fuel supply of glucose or fat promotes higher insulin and greater fetal fat deposition during the last trimester [65]. Women with gestational diabetes or mild glucose intolerance and obesity have at least a 3-fold greater risk of having an infant above the 90th percentile in body weight and percent body fat [66, 67]. Substantial data indicate that maternal obesity predisposes the infant to overweight, obesity and MetS [68–70].

Rapid weight gain in infancy has consistently been associated with a significantly higher risk of overweight or obesity in preschool and young children [71, 72] (fig. 3), as recently reviewed [88, 89]. More rapid childhood growth is also associated with a higher risk of obesity in adult life [90], insulin resistance [91], components of MetS [92] and a more atherogenic lipid profile in adolescence [93]. A high-protein infant formula also contributes to greater BMI and insulin-like growth factor-1 in infants at 6 months through 2 years of age compared with breastfed infants or those fed lower protein formula [94].

There appears to be a transgenerational effect of obesity, with the strength of the association between parental and childhood obesity increasing between generations [95], as shown in table 1. Few studies have examined this question, but a study on the birth information of mothers and their offspring from the Swedish Medical Birth Register reported that mothers born large for gestational age had increased risks of overweight and obesity and were at an increased risk of having a large-for-gestational-age infant as their BMI increased [96]. Interestingly, mothers born small for gestational age had the highest risk – 13 times greater – of having large-for-gestational-age offspring. Similarly, US data reported that the strongest persistence of BMI across generations occurred among those with higher BMI levels [97].

The final question discussed by Koletzko was whether the relative proportions of dietary n–6 and n–3 PUFA contribute to obesity and MetS risk. In many western countries, the increased consumption of n–6 PUFA, mainly from linoleic-acid-rich vegetable oils, and re-
duced intakes of n–3 PUFA parallel the sharp increase in the prevalence of obesity and type 2 diabetes [98–100]. Although the number of adipocytes is established in childhood [101], the greatest proliferation and differentiation of adipocyte precursor cells occurs during the 1st year of life and at prepuberty [102]. In animals, diets high in n–6 PUFA increase the differentiation and proliferation of preadipocytes, which increases the number of adipocytes and the accumulation of fat [103, 104]. Animals fed 35% fat diets containing either 1 or 8%E from linoleic acid or 8% linoleic acid plus 1% n–3 LC-PUFA exhibited increased obesity on the 8% linoleic acid diet, but had equivalent fat tissue when fed either level of linoleic acid supplemented with n–3 LC-PUFA [105]. Similar findings were reported in mice fed diets rich in linoleic acid or linoleic acid plus α-linolenic acid, where fat mass and adipocyte size at 8 weeks were higher in the linoleic acid–fed animals compared with those fed both n–6 and n–3 PUFA [106]. Little robust animal data exist on the effects of increased perinatal PUFA exposure on body fat mass in the offspring.

In humans, observational studies suggest that high maternal plasma n–6 PUFA at 34 weeks of gestation predicted offspring fat mass at 4 and 6 years of age [107]. A study of maternal PUFA intake and status during pregnancy and child adiposity at age 3 years reported that a higher ratio of n–6:n–3 PUFA in the maternal diet, plasma and cord blood was associated with higher child adiposity [108]. In the same study, higher maternal docosahexaenoic and eicosapentaenoic acid intakes were associated with a lower skinfold thickness measures at age 3. Fish oil supplementation in pregnancy was unrelated to adolescent obesity at 19 years of age [109]. A recent intervention study examined the reduction in the maternal intake of n–6:n–3 LC-PUFA during pregnancy and the first 4 months of lactation [110]. Participants were counseled to reduce their intake of arachidonic acid and consume a daily supplement providing 1,020 mg docosahexaenoic acid, 180 mg eicosapentaenoic acid and 9 mg of vitamin E. The control group was counseled to eat a healthy diet. Up to 12 months of age, there were no statistically significant differences in the fat mass or skinfold thickness measurements in the offspring of the intervention and control groups.

Overall, few randomized controlled trials have investigated different intakes of n–6 and n–3 PUFA in pregnancy and subsequent offspring obesity. Two reviews of human studies on child adiposity and maternal LC-PUFA intake reported inconsistent findings on PUFA intakes and offspring BMI or obesity [111, 112]. Thus, the quantity and quality of available data in humans permit no conclusions about LC-PUFA and childhood obesity.

Koletzko concluded that pre- and postnatal overfeeding increases the risk for obesity and associated disorders and that it is biologically plausible that diets high in n–6 PUFA or high in n–6:n–3 PUFA could have potential adverse effects on pre- and postnatal obesity. He noted that n–3 LC-PUFA may have potential benefits on insulin sensitivity and associated outcomes in overweight children and emphasized that high SFA diets should be avoided, but at this time evidence for a causal relationship is not available. Currently, there is no basis to change current recommendations on dietary fat quality in pregnancy, lactation and infancy.

Do High- or Low-Fat Diets Counteract MetS?

Weight loss is the first line of defense in MetS, affirmed Jennifer Fleming, Pennsylvania State University, University Park, Pa., USA. Weight reduction strategies have focused primarily on the effectiveness of reduced-carbohydrate (<50% total E) versus low-fat (<30%E) diets. Although both diets are associated with weight loss [113], intervention studies with reduced dietary fat have not consistently achieved positive long-term results on body weight or MetS criteria despite short-term weight loss. In contrast, reduced-carbohydrate diets have demonstrated improved blood lipid profiles, reduced blood pressure, plasma glucose and visceral adiposity, and have been associated with long-term weight loss (i.e. 2 years) [21]. A recent review by Schwingshackl and Hoffmann [114] supports these findings. However, Sacks et al. [115] reported no differences in weight loss after 2 years between those following low-fat (20%E), high-carbohydrate (55–65%E) versus high-fat (40%E), lower-carbohydrate (35–45%E) diets with varying protein content. However, the macronutrient targets of the diets were not met. Notably, the greatest weight loss occurred among those with the highest dietary compliance. This observation was reinforced by results from the A to Z weight loss study [116]. Collectively, research shows that beyond focusing on the macronutrient profile, it is important to identify a dietary pattern that can be followed long-term.

Emerging evidence suggests that certain dietary patterns may be more effective for weight loss in some overweight or obese groups depending on their metabolic status, particularly their insulin sensitivity. Risk factors for type 2 diabetes and cardiovascular disease vary substan-
tially among obese individuals, with insulin resistance characterizing those with the greatest risk [117].

A study comparing two reduced energy diets, either high in carbohydrates (60%E) and low in fat (20%E) or low in carbohydrates (40%E) and high in fat (40%E), in obese women who were either insulin sensitive or insulin resistant found that the insulin-sensitive women consuming the high-carbohydrate diet lost significantly more weight than insulin-sensitive women consuming the low-carbohydrate, high-fat diet (13.5 vs. 6.8% of initial body weight, respectively). In contrast, insulin-resistant women lost significantly more weight on the low-carbohydrate diet compared with the insulin-resistant women consuming the high-carbohydrate diet (13.4 vs. 8.5% of initial body weight, respectively) [118]. The investigators concluded that the state of insulin sensitivity determined the effectiveness of the macronutrient distribution in the weight loss diets consumed by these obese women.

In an 18-month study comparing a low-glycemic-load diet (40% carbohydrate and 35% fat) with a low-fat diet (55% carbohydrate and 20% fat) in obese young adults, participants with an insulin concentration above the median 30 min after an oral glucose dose consuming the low glycemic load diet experienced greater weight loss (–5.8 vs. –1.2 kg; p = 0.004) and decreased percent body fat (–2.6 vs. –0.9%; p = 0.03) than those consuming the low-fat diet [119]. The authors suggested that reducing the glycemic load might be especially important for achieving weight loss in individuals with high insulin secretion. Consistent with these findings was the observation that adherence to either a low-fat (≤10%E) or low-carbohydrate (≤50 g/day) diet among obese women was related to the insulin resistance status only for those on the low-fat diet [105]. Insulin-resistant participants were less likely to adhere to and lose weight on a low-fat diet compared to insulin-sensitive participants. Further, insulin-resistant women who consumed the low-carbohydrate diet experienced a significant reduction in their fasting insulin level compared with participants consuming the low-fat diet (–5.8 vs. –0.2 μIU/ml, p < 0.0001) or with insulin-sensitive women on the same diet (–5.8 vs. 0.1 μIU/ml, p < 0.001) [120].

When designing low-carbohydrate diets, the question arises whether protein or unsaturated fat should replace the carbohydrate. In a study comparing carbohydrate replacement with protein or monounsaturated fat in the diets of overweight and obese volunteers with elevated fasting insulin levels (>12 mU/l), investigators reported that weight loss (approx. 10 kg), improvements in insulin resistance and changes in cardiovascular risk factors did not differ between the groups after 12 weeks of energy restriction [121]. Fleming cautioned that the long-term effects of high-protein diets have not been extensively investigated, may be high in SFA and/or low in nutrient density, may be expensive or impractical, and are associated with declining adherence over time. Whether the replacement fat should be predominately monounsaturated or PUFA is unclear, as both types of fat are associated with improved lipid profile, increased insulin sensitivity, and lower blood pressure and abdominal fat when compared with dietary carbohydrate.

Fleming shared findings from a meta-analysis of 50 studies of the Mediterranean diet in patients with MetS, which reported significant associations between the diet and reduced waist circumference, increased HDL-cholesterol and lower triglyceride levels, lower systolic and diastolic blood pressures, and reduced glucose levels and insulin resistance [122]. These studies suggest that successful management of MetS is dependent on dietary patterns that have a moderate macronutrient composition and are nutrient dense.

The symposium participants agreed that preventing weight gain and tackling weight loss are key strategies for reducing MetS. Both low-fat and low-carbohydrate diets can lead to weight loss, but adherence to the dietary strategy trumps the macronutrient distribution. Avoiding high SFA diets contributes to a reduction in health risks for obese, MetS and diabetic patients. Healthy maternal weight at conception and in pregnancy is more important than weight gain during pregnancy in affecting the risk of obesity in the offspring. The effects of different PUFA distributions on MetS and weight loss await clarification.

Acknowledgments

Selected material from this paper was originally presented at the 20th International Congress of Nutrition in Granada, Spain, on September 19, 2013. Unilever, The Netherlands, provided financial assistance for this publication.

Disclosure Statement

The authors declare no conflicts of interest.
References


41 Buckley JD, Howe PR: Long-chain omega-3 polyunsaturated fatty acids may be beneficial for reducing obesity – a review. Nutrients 2010;2:1212–1230.


30 Kratz M, Callahan HS, Yang PY, Matthys CC, Weige DS: Dietary n-3 polyunsaturated fatty acids and energy balance in overweight or moderately obese men and women: a randomized controlled trial. Nutr Metab (Lond) 2009;6:24.


